Keyphrases
Relapsed or Refractory
94%
Hodgkin Lymphoma
76%
Rituximab
71%
Brentuximab Vedotin
69%
Progression-free Survival
57%
Diffuse Large B-cell Lymphoma (DLBCL)
57%
Follicular Lymphoma
53%
Chemotherapy
45%
Classical Hodgkin Lymphoma
40%
Overall Survival
40%
Phase II Study
38%
Non-Hodgkin Lymphoma
38%
Doxorubicin
36%
Relapsed Lymphoma
35%
Confidence Interval
31%
Lenalidomide
28%
Lymphoma
27%
Ibrutinib
26%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Chronic Lymphocytic Leukemia
25%
Mantle Cell Lymphoma
25%
Phase II Trial
23%
Overall Response Rate
22%
Adverse Events
21%
Complete Response
20%
Prednisone
20%
Clinical Trials
20%
Lymphoma Patients
20%
Cyclophosphamide
20%
Older Patients
18%
CD30
18%
Large B-cell Lymphoma
18%
Refractory Hodgkin Lymphoma
18%
Positron Emission Tomography
17%
Hazard Ratio
17%
Leukemia
16%
B-cell Lymphoma
16%
Vinblastine
16%
Peripheral T-cell Lymphoma
15%
Previously Untreated
15%
Complete Remission
15%
Radiation Therapy
15%
Etoposide
15%
Neutropenia
14%
Bleomycin
14%
Anaplastic Large Cell Lymphoma
14%
Mosunetuzumab
14%
NCCN Guidelines
14%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
Thrombocytopenia
14%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Rituximab
60%
Progression Free Survival
57%
Brentuximab Vedotin
55%
Diffuse Large B-Cell Lymphoma
50%
Diseases
47%
Classical Hodgkin Lymphoma
45%
Overall Survival
44%
Non-Hodgkin Lymphoma
40%
Follicular Lymphoma
37%
Doxorubicin
29%
Clinical Trial
29%
Adriamycin Bleomycin Vinblastine Dacarbazine
26%
Radiation Therapy
25%
Mantle Cell Lymphoma
23%
Ibrutinib
22%
Arm
22%
B-Cell Chronic Lymphocytic Leukemia
22%
Positron Emission Tomography
22%
Large-Cell Lymphoma
22%
Neoplasm
21%
Adverse Event
21%
Oncology
21%
B-Cell Lymphoma
21%
Malignant Neoplasm
19%
Lenalidomide
19%
Cyclophosphamide
18%
Bendamustine
17%
B Cell
17%
Transplantation
17%
Prednisone
16%
Vincristine
13%
Hazard Ratio
13%
Peripheral T-Cell Lymphoma
13%
Anaplastic Large Cell Lymphoma
12%
Chimeric Antigen Receptor T-Cell Immunotherapy
11%
Polyethylene Terephthalate
11%
Prognostic Factor
11%
Stem Cell Transplant
11%
Vinblastine
11%
Autologous Stem Cell Transplantation
11%
Leukemia
10%
Axicabtagene Ciloleucel
10%
Nivolumab
10%
Chimeric Antigen Receptor T-Cell
10%
Immunotherapy
10%
Cytokine Release Syndrome
10%
T Cell
10%
Neutropenia
10%
Monoclonal Antibody
10%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
72%
Hodgkin Disease
63%
Nonhodgkin Lymphoma
56%
Brentuximab Vedotin
51%
Progression Free Survival
50%
Chemotherapy
50%
Follicular Lymphoma
46%
Diffuse Large B Cell Lymphoma
45%
Doxorubicin
38%
Overall Survival
37%
Diseases
36%
Adverse Event
29%
Remission
26%
Lenalidomide
26%
Classical Hodgkin Lymphoma
22%
Clinical Trial
21%
Cyclophosphamide
21%
Malignant Neoplasm
20%
Bendamustine
19%
B Cell Lymphoma
18%
Mantle Cell Lymphoma
18%
Vincristine
18%
Ibrutinib
17%
Neoplasm
17%
Prednisone
17%
Chronic Lymphatic Leukemia
15%
Anaplastic Large Cell Lymphoma
15%
Chimeric Antigen Receptor
14%
Large Cell Lymphoma
14%
Leukemia
14%
Etoposide
13%
Neutropenia
13%
Phase II Trials
13%
Ibritumomab Tiuxetan
12%
Mosunetuzumab
12%
Thrombocytopenia
12%
Immunotherapy
12%
Peripheral T Cell Lymphoma
12%
Cytokine Release Syndrome
11%
Polyethylene Terephthalate
10%
Bortezomib
10%
Survival Rate
10%
Placebo
10%
Vinblastine
9%
Tolerability
9%
Antibody Drug Conjugate
8%
Dacarbazine
8%
Bleomycin
8%
Bispecific Antibody
8%
Maximum Tolerated Dose
8%